Retatrutide approval timeline: where it stands for Canada

What has to happen before retatrutide reaches a Canadian pharmacy

People read a trial headline and assume a prescription is a few months away. It is not, and the gap is measured in years. Four things have to land.

1. A filing with a regulator

Nothing moves until the company asks. Lilly has said it plans to submit to the US FDA in the first quarter of 2027. It has said nothing in public about Canada. Health Canada does not have to wait for the Americans, but it cannot review a file it has not received.

2. Health Canada's screening and review

Once a submission arrives, Health Canada first screens it to confirm it is complete, then reviews it. The published targets are 45 days for screening and 300 days for review. A drug granted priority review gets a 180-day review target instead.

3. A Notice of Compliance

This is the authorization itself. Until Health Canada issues it, retatrutide is not a medicine in Canada in any legal sense. It cannot be imported for sale, stocked, advertised or prescribed.

4. Price, coverage and supply

Authorization does not put boxes on shelves. The company sets a price, Canada's Drug Agency reviews whether public plans should pay, each province decides its own coverage, and wholesalers stock pharmacies. A Canadian price does not exist before this point, because there is nothing to price.

Retatrutide FDA approval: the US step

Much of what Canadians read about timing is about the United States, so it helps to know what is and is not on the record there.

• On the record: on August 5, 2026, Lilly told investors its trial data was complete and that it plans to submit a Biologics License Application in the first quarter of 2027.
• Also on the record: the uses it named were obesity, obstructive sleep apnea and knee osteoarthritis pain.
• Not on the record: a filing date, an FDA acceptance, or a decision date. None of those can exist before the application does.

A US filing would not start any Canadian clock. I still treat it as the clearest signal to watch, because it will show that the application exists in finished form.

Will every use of retatrutide be approved at once?

Probably not. Lilly named three uses in its filing plan, and type 2 diabetes was not among them. The diabetes trials form a separate programme, and some are still running.

Health Canada judges each use on its own evidence. A drug can be authorized for weight management first and for another condition later, or the other way round. So "approved in Canada" may arrive in stages, and the first stage may not be the one you are waiting for.

How long could the retatrutide approval timeline run?

I will show the arithmetic, because it is more useful than a guess dressed up as a date.

Health Canada's two targets add up to 345 days, a little under a year. That clock starts when a Canadian submission is filed. So take the most optimistic case: Lilly files in Canada in the first quarter of 2027, the same window as its US plan, and Health Canada hits both targets. The decision would land around the start of 2028.

Every part of that sentence is an assumption. No Canadian filing date has been announced. The targets are standards, not promises. And step four comes after the decision. My honest read is that a Canadian pharmacy filling a retatrutide prescription before 2028 would need everything to go right, and I would not plan around it.

What could move the retatrutide timeline

• A Canadian filing announcement. This is the one to watch. The day retatrutide appears on Health Canada's list of submissions under review, the clock becomes real.
• Priority review. If Health Canada grants it, the review target drops from 300 days to 180. No request has been made public.
• The head-to-head result. TRIUMPH-5 compares retatrutide with tirzepatide. The registry estimates its main data collection ends in November 2026. It will not change the filing plan, but it will shape how doctors and payers receive the drug.
• Questions from a regulator. Reviews can stretch when an agency asks for more analysis. That cannot be predicted from outside.

Why this page has no retatrutide release date

Plenty of sites will give you a month and a year. I looked for the source behind those dates and found none. They are built by adding average review times to a filing that has not happened.

What we do instead is date each event that has occurred, link where it came from, and stamp the page with the day it was last checked. If the stamp is recent and the newest dated entry is weeks old, that tells you something true: nothing has moved. When something does, the new entry goes on the timeline first and the other pages are updated from it.

Common questions about the retatrutide approval timeline